Papers [Regulatives / Guidelines]

posted by Mahmoud  – Jordan, 2021-09-17 13:31 (372 d 12:19 ago) – Posting: # 22580
Views: 1,623

Dear all

Dr Anders Fuglsang discussed in his paper

Mitigation of the convergence issues associated with semi-replicated bioequivalence data. Pharmaceutical Statistics. 2021;1–3
used the proc mixed in RTR/TRR/RRT design in ABE

I think that using proc mixed to fit RTR/TRR/RRT design is not suitable, because in most cases proc mixed produced Estimated G matrix is not positive definite.

So proc GLM recommended by FDA and Emea is more appropriate in the Semi-replicated designs


Edit: Post moved. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,385 posts in 4,684 threads, 1,594 registered users;
online 11 (0 registered, 11 guests [including 5 identified bots]).
Forum time: Sunday 01:50 CEST (Europe/Vienna)

You really don’t know what you don’t know until you write about it.
Then, everyone knows what you don’t know.    Rod Machado

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz